Literature DB >> 7667295

Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.

A J George1, F Jamar, M S Tai, B T Heelan, G P Adams, J E McCartney, L L Houston, L M Weiner, H Oppermann, A M Peters.   

Abstract

We describe a method to facilitate radioimaging with technetium-99m (99mTc) by genetic incorporation of a 99mTc chelation site in recombinant single-chain Fv (sFv) antibody proteins. This method relies on fusion of the sFv C terminus with a Gly4Cys peptide that specifically coordinates 99mTc. By using analogues of the 26-10 anti-digoxin sFv as our primary model, we find that addition of the chelate peptide, to form 26-10-1 sFv', does not alter the antigen-binding affinity of sFv. We have demonstrated nearly quantitative chelation of 0.5-50 mCi of 99mTc per mg of 26-10-1 sFv' (1 Ci = 37 GBq). These 99mTc-labeled sFv' complexes are highly stable to challenge with saline buffers, plasma, or diethylenetriaminepentaacetic acid. We find that the 99mTc-labeled 741F8-1 sFv', specific for the c-erbB-2 tumor-associated antigen, is effective in imaging human ovarian carcinoma in a scid mouse tumor xenograft model. This fusion chelate methodology should be applicable to diagnostic imaging with 99mTc and radioimmunotherapy with 186Re or 188Re, and its use could extend beyond the sFv' to other engineered antibodies, recombinant proteins, and synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667295      PMCID: PMC41156          DOI: 10.1073/pnas.92.18.8358

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Recombinant antibody-metallothionein: design and evaluation for radioimmunoimaging.

Authors:  C Das; P V Kulkarni; A Constantinescu; P Antich; F R Blattner; P W Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

2.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  Phage libraries for generation of clinically useful antibodies.

Authors:  K A Chester; R H Begent; L Robson; P Keep; R B Pedley; J A Boden; G Boxer; A Green; G Winter; O Cochet
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

4.  Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule.

Authors:  A J George; J A Titus; C R Jost; I Kurucz; P Perez; S M Andrew; P J Nicholls; J S Huston; D M Segal
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

5.  Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.

Authors:  G P Adams; J E McCartney; M S Tai; H Oppermann; J S Huston; W F Stafford; M A Bookman; I Fand; L L Houston; L M Weiner
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

6.  Making antibody fragments using phage display libraries.

Authors:  T Clackson; H R Hoogenboom; A D Griffiths; G Winter
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

7.  Metal-binding chimeric antibodies expressed in Escherichia coli.

Authors:  J R Sawyer; P W Tucker; F R Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

8.  Technetium-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals.

Authors:  A M Verbruggen; D L Nosco; C G Van Nerom; G M Bormans; P J Adriaens; M J De Roo
Journal:  J Nucl Med       Date:  1992-04       Impact factor: 10.057

9.  Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.

Authors:  M E Schott; D E Milenic; T Yokota; M Whitlow; J F Wood; W A Fordyce; R C Cheng; J Schlom
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

10.  Rapid infarct imaging with a technetium-99m-labeled antimyosin recombinant single-chain Fv: evaluation in a canine model of acute myocardial infarction.

Authors:  M A Nedelman; D J Shealy; R Boulin; E Brunt; J I Seasholtz; I E Allen; J E McCartney; F D Warren; H Oppermann; R H Pang
Journal:  J Nucl Med       Date:  1993-02       Impact factor: 10.057

View more
  7 in total

Review 1.  The production and application of single-chain antibody fragments.

Authors:  D Blazek; V Celer
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

Review 2.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

3.  Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region.

Authors:  P C Keck; J S Huston
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

Review 4.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 2: Peptide Tags and Unnatural Amino Acids.

Authors:  Pierre Adumeau; Sai Kiran Sharma; Colleen Brent; Brian M Zeglis
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

5.  Binding of ReO4(-) with an engineered MoO4(2-)-binding protein: towards a new approach in radiopharmaceutical applications.

Authors:  Baikuntha P Aryal; Pedro Brugarolas; Chuan He
Journal:  J Biol Inorg Chem       Date:  2011-08-23       Impact factor: 3.358

6.  Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2.

Authors:  Shannon J Sirk; Tove Olafsen; Bhaswati Barat; Karl B Bauer; Anna M Wu
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

7.  Introducing site-specific cysteines into nanobodies for mercury labelling allows de novo phasing of their crystal structures.

Authors:  Simon Boje Hansen; Nick Stub Laursen; Gregers Rom Andersen; Kasper R Andersen
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-09-27       Impact factor: 7.652

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.